by Payash Bahuguna | May 10, 2022 | PR
Iktok and Sygnature Discovery announce their collaboration in Artificial Intelligence for de novo drug design. Under the 3-year agreement, Sygnature will deploy Iktos’ de novo generative design software Makya™, which will be used by Sygnature scientists to facilitate...
by Payash Bahuguna | Apr 26, 2022 | Job vacancies
Apply Here Qui sommes nous Iktos développe une technologie propriétaire alliant intelligence artificielle et connaissances en chimie médicinale pour la conception et la génération de nouvelles molécules. Basés à Paris dans un large bâtiment Haussmannien à...
by Payash Bahuguna | Apr 26, 2022 | Job vacancies
Apply Here Qui sommes nous Iktos développe une technologie propriétaire alliant intelligence artificielle et connaissances en chimie médicinale pour la conception et la génération de nouvelles molécules. Basés à Paris dans un large bâtiment Haussmannien à...
by Payash Bahuguna | Apr 26, 2022 | Job vacancies
Apply Here About Iktos Iktos is an applied artificial intelligence start-up that helps chemistry researchers improve their molecular discovery, drug design process and synthetic planning in early phases of the pharmaceutical drug discovery phase. This goes through...
by Payash Bahuguna | Apr 26, 2022 | Job vacancies
Apply Here About Iktos Iktos is an applied artificial intelligence start-up that helps chemistry researchers improve their molecular discovery, drug design process and synthetic planning in early phases of the pharmaceutical drug discovery phase. This goes through...
